<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04358952</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/20/0117</org_study_id>
    <secondary_id>2020-A00852-37</secondary_id>
    <nct_id>NCT04358952</nct_id>
  </id_info>
  <brief_title>Myocardial Involvement of Severe Acute Respiratory Syndrome-Cov-2 (Covid19) Infected Patients</brief_title>
  <acronym>COCARDE</acronym>
  <official_title>Imaging Cardiac Phenotype of SARS-Cov-2 (Covid19) Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effects of severe acute respiratory syndrome SARS-Cov-2 (Covid-19) on the myocardium and&#xD;
      their role in the clinical course of infected patients are still unknown. Epidemiological&#xD;
      studies report biological myocardial involvement in 10 to 25% of cases. The objective of this&#xD;
      study is to cardiac phenotype using comprehensive cardiac imaging tools of patients infected&#xD;
      with Covid 19 in order to explore the functional impact of the infection on the myocardium.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A large population of Covid 19 infected patients of different ages and severity levels will&#xD;
      be explored by transthoracic echocardiography with measurement of myocardial functional&#xD;
      parameters such as ejection fraction, longitudinal strain and relaxation parameters and will&#xD;
      be compared to an uninfected population paired for age and sex.&#xD;
&#xD;
      Patients with biological myocardial involvement will be followed to determine the evolution&#xD;
      of their myocardial functional parameters during the course of the infection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 4, 2020</start_date>
  <completion_date type="Actual">April 2, 2021</completion_date>
  <primary_completion_date type="Actual">April 2, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular function</measure>
    <time_frame>Day 0</time_frame>
    <description>Left ventricular function evaluated by global longitudinal strain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Left ventricular function</measure>
    <time_frame>Day 3</time_frame>
    <description>Left ventricular function evaluated by global longitudinal strain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Left ventricular function</measure>
    <time_frame>Day 7</time_frame>
    <description>Left ventricular function evaluated by global longitudinal strain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>inflammatory biological parameters</measure>
    <time_frame>Day 0</time_frame>
    <description>Cytokine rate</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">122</enrollment>
  <condition>Cardiomyopathies</condition>
  <arm_group>
    <arm_group_label>COVID + patients</arm_group_label>
    <description>Major patients hospitalized for respiratory criteria for SARS-Cov-2 infection confirmed by RT-PCR</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Global Longitudinal Strain</intervention_name>
    <description>Electrocardiogram with measure of the Global Longitudinal Strain to evaluate myocardiac dysfunction</description>
    <arm_group_label>COVID + patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Inflammatory cytokines&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Major patients hospitalized for respiratory criteria for SARS-Cov-2 infection confirmed by&#xD;
        RT-PCR&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Major patients hospitalized for respiratory criteria for SARS-Cov-2 infection&#xD;
             confirmed by RT-PCR&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Underage patients. Patients refusing to participate in research. Patients with a&#xD;
             history of heart disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent MINVILLE, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UHToulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 9, 2020</study_first_submitted>
  <study_first_submitted_qc>April 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>May 28, 2021</last_update_submitted>
  <last_update_submitted_qc>May 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Left ventricular systolic function</keyword>
  <keyword>left ventricular diastolic function</keyword>
  <keyword>global longitudinal strain</keyword>
  <keyword>SARS-Cov-2</keyword>
  <keyword>Covid-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

